Pekar et al. engineered a bispecific engager that recognizes NKp30 on the NK cells and EGFR on the tumor cells, using an antigen binding fragment (Fab) arm derived from cetuximab, and showed that NKp30 engagement was sufficient to induce NK cell cytotoxicity. Here, NCR3 is linked to neoplasm.